Offering HIV screening at a syringe services program for people who inject drugs 2Providing HIV testing to participants in a clinical trial for an HIV vaccine, 3 months after receiving the s

POSSIBLE ANSWERS:
ANTIBODY-BASED HIV TEST
VIRAL LOAD/VIRAL HIV TEST
1Offering HIV screening at a syringe services program for people who inject drugs
2Providing HIV testing to participants in a clinical trial for an HIV vaccine, 3 months after receiving the study vaccine
3Testing newborns for HIV at a labor & delivery center serving pregnant people with HIV in Uganda
4.Providing HIV testing as part of routine primary care services to adults and adolescents in Kenya
5.An search-and-rescue worker presents 4 days after a needlestick exposure in the field from a person with unknown HIV status and unknown ART use status. She was unable to receive PEP within the 72-hour window after exposure because she was in a remote wilderness location and has just now returned to be able to access health care
6. Providing quarterly HIV testing to transgender women receiving oral PrEP in Seattle
Which of the following statements is/are true about HIV vaccines?
Group of answer choices
We will never be able to develop an HIV vaccine because there is no natural immunity to HIV.
Current approaches to developing an HIV vaccine include mRNA vaccines and protein subunit vaccines to induce the immune system to produce broadly neutralizing antibodies.
Because we have several kinds of highly-effective oral and injectable PrEP, there is no longer a need for an HIV vaccine.
The RV144 HIV Vaccine Trial showed a modest (31%) reduction of HIV incidence in people who received vaccine compared to placebo, providing evidence that a highly effective vaccine could possibly be achieved.
There have not been any Phase 3 efficacy studies for an HIV vaccine conducted in the last 6 years.